Ionis Pharmaceuticals, Inc. (IONS) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and welcome to IONI's first quarter 2026 financial results conference call. As a reminder, this call is being recorded. At this time, I would like to turn the call over to Wade Wolk, Senior Vice President of Investor Relations, to lead off the call. Please begin. Thank you, Sabrina. Before we begin, I encourage everyone to go to the investor section of the IONIS website to view the press release and related financial tables we will be discussing today, including a reconciliation of GAAP to non-GAAP financials. We believe non-GAAP financial results better represent the economics of our business and how we manage our business. We have also posted slides on our website that accompany today's call. With me this morning are Brett Monia, Chief Executive Officer, Kyle Genet, Chief Global Product Strategy Officer, and Beth Haugen, Chief Financial Officer. Holly Kordasiewicz, Chief Development Officer, Eugene Schneider, Chief Clinical Development Officer, and Eric Swayze, Executive Vice President of Research, will also join us for the Q&A portion of the call. I'd like to draw your attention to slide three, which contains our forward-looking language statement. During this call, we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional detail. And with that, I'll turn the call over to Brett. Thanks, Wade. Good morning, everyone, and thank you for joining us today. IONIS entered 2026 with significant momentum, which continued to accelerate through the first quarter of this year. Our performance to date highlights our strong executi...